Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A stem cell therapy called bemdaneprocel is showing promise for Parkinson's disease, with a favorable safety profile sustained over four years. The treatment works by replacing dopamine-producing neurons in the brain — essentially rebuilding what the disease destroys. Motor function scores also trended toward improvement in both low- and high-dose groups.
A stem cell therapy called bemdaneprocel is turning heads in the Parkinson's world, with new 4-year data showing a solid safety profile and encouraging signs of sustained benefit. Presented at the 151st Annual Meeting of the American Neurological Association, the findings come from a 12-patient study where participants received dopaminergic neuron progenitor cells — derived from allogenic pluripotent stem cells — surgically implanted into the posterior putamen. Unlike levodopa or deep brain stimulation, this approach aims to rebuild the brain's dopamine system rather than just manage symptoms.
Most treatment-emergent adverse events were mild or moderate, with no deaths or discontinuations due to treatment. Neuroimaging showed signs of cell survival in the putamen, while motor function scores improved over 48 months in both dose groups — a meaningful signal for a disease known for relentless progression.
By the Numbers:
Why it matters: Current Parkinson's treatments manage symptoms but can't stop — or reverse — the underlying neurodegeneration. Bemdaneprocel's "restore, don't just modulate" approach could represent a genuine paradigm shift, offering patients a hardware-free, potentially longer-lasting alternative.
